Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Critical Reviews in Oncology/Hematology|June 7, 2025
Challenges facing CAR T-cell immunotherapy in multiple myelomaWanyan Ouyang, Jian-Qing MiMedicine|November 2, 2018
Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia: A case reportWanyan Ouyang, Xiaohong Zhao, Shiyun Lu, et al.Critical Reviews in Oncology/Hematology|September 18, 2016
Aptamers in hematological malignancies and their potential therapeutic implicationsWanyan Ouyang, Ziqiang Yu, Xiaohong Zhao, et al.Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 11, 2014
Two novel mutations identified in a type 3 von Willebrand disease patientWanyan Ouyang, Ziqiang Yu, Jie Yin, et al.BMC Cancer|April 2, 2024
Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myelomaYi Tao, Shiwei Jin, Dan Yang, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|March 11, 2014
[Clinical studies of 162 patients with von Willebrand disease]Wanyan Ouyang, Ziqiang Yu, Jie Yin, et al.Journal of Hematology & Oncology|June 20, 2015
Mutations in the D1 domain of von Willebrand factor impair their propeptide-dependent multimerization, intracellular trafficking and secretionJie Yin, Zhenni Ma, Jian Su, et al.BMC Medicine|May 2, 2025
Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogeneticsYi Tao, Shi-Wei Jin, Zhe Wang, et al.British Journal of Haematology|October 4, 2024
Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed/refractory diseaseWeiyang Liu, Cheng Wang, Wanyan Ouyang, et al.Journal for Immunotherapy of Cancer|April 8, 2024
PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustionWanyan Ouyang, Shi-Wei Jin, Nan Xu, et al.Pageof 2